- Today, we revisit biopharma concern Supernus Pharmaceuticals whose just reported 4th quarter results that triggered a near 10% selloff in its stock.
- However, the company reported solid results for the quarter and year and navigated the impacts of the pandemic quite well in 2020.
- Investors seem to be overlooking the potential FDA approval of another drug for the company's pipeline in 2021 as well as a huge cash hoard on its balance sheet.
- We update our investment analysis on Supernus Pharmaceuticals in the paragraphs that follow.
For further details see:
Supernus Pharmaceuticals: Solid Quarter, Solid Stock